THE "NEW" PROSTATE CANCER INFOLINK

HOME

• About The “New” Prostate Cancer InfoLink
  • Some background
  • How is this service financed?
  • Management and other personnel
  • Scientific Advisory Board
• Polls and surveys
  • Who’s using The “New” Prostate Cancer InfoLink? (October 16-23, 2008)
• In the news
  • Media commentary on and articles about The “New” Prostate Cancer InfoLink
• The newsroom
  • Who to contact, and how
  • Electronic media kit
  • Media releases
• The “New” Prostate Cancer InfoLink News Blog
• The “New” Prostate Cancer InfoLink Social Network
• Site map
• Copyright

RISK AND PREVENTION

• What is prostate cancer?
• Finding cancer in a man’s prostate is NORMAL!
• Who is at risk for prostate cancer?
  • Genetics and prostate cancer risk
  • Age and prostate cancer risk
  • Race and prostate cancer risk
  • Diet and the environment
  • Does having a vasectomy cause prostate cancer?
• Are all cases of prostate cancer equal in risk?
• The PCPT prostate cancer risk calculator
• The Sunnybrook prostate cancer risk calculator
• Projection of prostate cancer risk in Europe
• PSA as a long-term marker for risk
• Prevention: an introduction (with video presentation)
  • The importance of exercise and wellness
  • Is extract of pomegranate an elixir of life?
  • Finasteride and the Prostate Cancer Prevention Trial (PCPT)
  • Dutasteride and the REDUCE trial
  • The prevention of prostate cancer with 5α-reductase inhibitors (5-ARIs)
  • Selenium, vitamin E, and the SELECT trial
  • The Physicians’ Health Study II randomized controlled trial
  • Other major prostate cancer prevention trials
• Important articles on prostate cancer prevention
• Are you taking Propecia (finasteride) for hair loss?

DIAGNOSIS

• For newly diagnosed patients …
• Prostate cancer screening and early detection (and video presentation)
  • The role of PSA today (in prostate cancer diagnosis)
  • Is regular prostate cancer testing appropriate for everyone?
  • Prostate cancer screening and the PLCO trial
  • Prostate cancer screening and the ERSPC trial
  • The Tyrol, Austria and King County, Washington screening studies
  • Risk-related screening
  • For men over 75: The Iowa Prostate Cancer Consensus
• Signs and symptoms of prostate cancer
• Digital rectal examination or DRE (and video presentation)
• Prostate specific antigen testing
  • Different PSA tests and how they can be used
  • PSA velocity: is it important to prostate cancer risk?
• Diagnosis: an introduction
• Prostate biopsy: how it’s done and what’s involved (and two video presentations)
• Your biopsy results: how to read them and what they mean
• What on Earth is PIN?
• That’s not what ASAP stands for! Is it?
• Other important tests
  • The prostatic acid phosphatase or PAP test
  • MRI, CT, and other imaging tests
  • Bone scans
  • Evolving tests for new markers
• The spouse/partner’ roles and perspectives
• Important articles on prostate cancer diagnosis

MANAGEMENT

• In the beginning …
• Staging and grading (with video presentation)
  • Clinical staging (with video presentation)
  • Pathological staging
  • Understanding Gleason grading (with video presentation)
    • Gleason grades 1 and 2
    • Gleason grade 3
    • Gleason grade 4
    • Gleason grade 5
  • The Gleason score
  • Misstaging and misgrading: it’s a problem
• Treatment: the absolute basics
• The natural history of conservatively treated prostate cancer
• First-line treatments for early stage (localized) disease
  • What! You mean I’m going to have to CHOOSE?
  • Comparative data on the various options for treatment of early stage (localized) prostate cancer
    • Watchful waiting vs. radical prostatectomy: the Scandinavian trial
    • LRP vs. RRP: the Memorial Sloan-Kettering data
  • Active surveillance and watchful waiting (with two video presentations)
    • The downsides of conservative management
  • Established surgical treatments
    • Radical prostatectomy: a brief historical note
    • Open radical retropublic prostatectomy (RRP)
    • Open radical perineal prostatectomy (RPP)
    • Minimally invasive (laparoscopic) radical prostatectomy (LRP)
      • Who needs a robot — and why?
  • Established radiotherapeutic treatments
    • External (photon) beam radiation therapy (EBRT)
    • Proton beam radiation therapy (PBRT)
    • Permanent implant brachytherapy
    • Temporary implant brachytherapy
    • Brachytherapy + external beam combination therapies
  • Investigational forms of radiation therapy
    • RapidArc radiotherapy
    • CyberKnife radiotherapy (stereotactic body radiation therapy)
  • Other forms of first-line treatment
    • Cryotherapy
    • High intensity focused ultrasound (HIFU)
  • Hormone therapy
  • Focal therapy: a future possibility
• Side effects and complications of first-line therapy: an overview
  • The “Quality of Life and Satisfaction With Outcomes” study
  • Erectile dysfunction (risk, natural history, and management)
  • Urinary incontinence
  • Painful defecation
• When first-line treatment fails the patient with early stage disease
  • Establishing risk and prognosis
  • Expectant management (e.g., watchful waiting and active surveillance)
  • The role of salvage surgery
  • The role of salvage radiation therapy
  • The role(s) of hormone therapy
  • Investigational forms of salvage therapy
• First-line treatment for non-localized disease
  • Active surveillance/watchful waiting
  • The role of surgery (surgical debulking)
  • External beam radiotherapy
  • Hormonal therapies
  • Investigational therapies
• Treatment for advanced (non-metastatic) disease
  • Hormonal therapies
  • Immunotherapy
  • Investigational therapies
• The treatment of metastatic disease (and video presentation)
  • Active surveillance (watchful waiting)
  • Hormonal therapies
    • Orchiectomy
    • Luteinizing hormone releasing hormone (LHRH) agonists
    • Luteinizing hormone releasing hormone (LHRH) antagonists
    • Nonsteroidal antiandrogens
  • Immunotherapy
  • Investigational therapies
• The treatment of hormone-refractory disease
  • Anti-androgen withdrawal
  • Chemotherapy
  • Immunotherapy
• Palliative treatment in late-stage disease
  • Management of severe bone pain
  • Management of fractures and other complications
• Monitoring treatment: an overview
  • The role of PSA tests
  • The role of bone scans
  • The roles of other tests
• Alternative and complementary medicines
• Side effects and complications of hormonal therapies
  • Gynecomastia (swelling and tenderness of the breast)
  • Bone loss
  • Hot flashes
  • Mood changes and depression
• Living with prostate cancer
  • When curative therapy fails
  • The spouse or partner’s perspective
  • The importance of state of mind
  • Introduction to integrative oncology (by Barrie Cassileth, MS, PhD)
  • Exercise, wellness, and response to prostate cancer therapy
• Important articles on the management of prostate cancer

ASK QUESTIONS

• Ask Arnon
• Ask Arthur
• Ask Amy

TIPS AND TOOLS

• What cancer cannot do
• Major US-based prostate cancer web sites and organizations
• Non-US-based prostate cancer web sites and organizations
• Views from the “other side”: personal reflections about prostate cancer from two urological oncologists
• Tips
  • The “top 10″ facts you need to know
  • Finding the prostate cancer specialist who is right for YOU
  • How to pick a prostate cancer surgeon (by Arnon Krongrad, MD)
  • How to select your brachytherapist (by Michael F. Sarosdy, MD)
  • Nine tips for picking a radiation oncologist to treat your prostate cancer (by Matthew Katz, MD)
  • Finding the medical oncologist who’s right for you: one specialist’s opinion (by Andrew Armstrong, MD, MSc)
  • Minimally invasive surgery: an overview
• Tools
  • Prostate cancer-related abbreviations
  • Risk assessment tools
    • The PCPT prostate cancer risk calculator
    • The Sunnybrook prostate cancer risk calculator
  • Prognostic tools
    • The Partin tables and how to use them (with video presentation)
    • The Han tables and how to use them
    • The Kattan nomograms and how to use them
    • Other prognostic tables and nomograms
  • Finding out about clinical trials
    • Important things you need to know
    • Clinical Trials Advocacy Group — Prostate Cancer
    • ClinicalTrials.gov
    • The Nexcura database
    • CenterWatch clinical trials notification services

Content of this page last reviewed and updated May 24, 2009